1. | | Recruiting | Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Conditions: Hypopharyngeal Cancer; Laryngeal Cancer; lip and oral cavity cancer; metastatic squamous neck cancer with occult primary; Nasopharyngeal Cancer; ... |
2. | | Completed | Chemotherapy in Treating Patients Who Have Hematologic Cancer Conditions: refractory chronic lymphocytic leukemia; recurrent adult acute myeloid leukemia; refractory anemia with excess blasts in transformation; ... |
3. | | Completed | Chemotherapy in Treating Patients With Prostate Cancer Conditions: stage IV prostate cancer; recurrent prostate cancer |
4. | | Completed | Chemotherapy in Treating Patients With Recurrent, Metastatic, or Unresectable Ovarian, Fallopian Tube, or Peritoneal Cancer Conditions: recurrent ovarian epithelial cancer; peritoneal cavity cancer; Fallopian Tube Cancer; stage III ovarian epithelial cancer; ... |
5. | | Completed | Chemotherapy in Treating Women With Metastatic Breast Cancer Conditions: stage IV breast cancer; recurrent breast cancer |
6. | | Recruiting | DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors Condition: unspecified adult solid tumor, protocol specific |
7. | | Recruiting | DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma Conditions: Colon Cancer; Rectal Cancer |
8. | | Completed | DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Conditions: childhood Hodgkin's lymphoma; childhood brain tumor; childhood non-Hodgkin's lymphoma; childhood solid tumor |
9. | | No longer recruiting | DX-8951f in Treating Patients With Biliary Cancer Conditions: localized gallbladder cancer; cholangiocarcinoma of the gallbladder; localized extrahepatic bile duct cancer; recurrent gallbladder cancer; ... |
10. | | No longer recruiting | DX-8951f in Treating Patients With Liver Cancer Conditions: recurrent adult primary liver cancer; advanced adult primary liver cancer; localized resectable adult primary liver cancer; ... |
11. | | No longer recruiting | DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas Conditions: recurrent pancreatic cancer; duct cell adenocarcinoma of the pancreas; stage IV pancreatic cancer; adenocarcinoma of the pancreas |
12. | | Suspended | DX-8951f in Treating Patients With Metastatic Stomach Cancer Conditions: stage III gastric cancer; stage IV gastric cancer; recurrent gastric cancer; stage III esophageal cancer; stage IV esophageal cancer; ... |
13. | | No longer recruiting | DX-8951f in Treating Previously Untreated Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Conditions: stage IV non-small cell lung cancer; stage IIIB non-small cell lung cancer; recurrent non-small cell lung cancer |
14. | | Suspended | DX-8951f in Treating Women Who Have Advanced or Recurrent Cancer of the Cervix Conditions: stage III cervical cancer; stage IV cervical cancer; recurrent cervical cancer; cervical squamous cell carcinoma |
15. | | No longer recruiting | Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma Conditions: previously treated childhood rhabdomyosarcoma; recurrent childhood rhabdomyosarcoma |
16. | | No longer recruiting | Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor Conditions: Ewing's family of tumors; childhood soft tissue sarcoma |
17. | | No longer recruiting | Gemcitabine With or Without Exatecan Mesylate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Conditions: stage III pancreatic cancer; stage IVA pancreatic cancer; stage IVB pancreatic cancer |
18. | | Completed | A Phase I Trial of Tecogalan sodium ( DS-4152 ) Administered as an Infusion Twice Weekly for 21 Days. Conditions: Sarcoma, Kaposi; HIV Infections |
19. | | Completed | A Phase I Trial of Tecogalan sodium ( DS-4152 ) Administered as an Infusion Weekly x 4 Conditions: Sarcoma, Kaposi; HIV Infections |
20. | | Completed | A Phase I Trial of Tecogalan sodium (DS-4152) Administered as an Infusion Every 21 Days Conditions: Sarcoma, Kaposi; HIV Infections |
21. | | Recruiting | Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors Condition: unspecified adult solid tumor, protocol specific |
22. | | Recruiting | Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Condition: adult soft tissue sarcoma |
23. | | Suspended | Soblidotin in Treating Patients With Progressive Locally Advanced or Metastatic Non-Small Cell Lung Cancer Conditions: stage IIIA non-small cell lung cancer; stage IIIB non-small cell lung cancer; stage IV non-small cell lung cancer; ... |
24. | | Recruiting | Study of HGF via Plasmid Vector to Improve Perfusion in Critical Limb Ischemia Conditions: Arterial Occlusive Disease; Peripheral Vascular Disease; Ischemia |
25. | | Completed | A Study of Tecogalan Sodium Conditions: Sarcoma, Kaposi; HIV Infections |